BRAF and melanoma: A total of 41.6% of patients had stage IIIC melanoma (Table 1); BRAF mutation V600E was present in 87.1% and V600K in 8% of tumors, median RFS was not reached overall (Figure 1A) and among patients who completed the 12 months treatment, while for patients who did not complete treatment, adjuvant combination was 37.9 months (95%CI, 20.44-NE, p < 0.0001) (Figure 1B).